Remotely controlled nanofluidic implantable platform for tunable drug delivery

Research output: Contribution to journalArticle

Nicola Di Trani, Antonia Silvestri, Giacomo Bruno, Thomas Geninatti, Ying Xuan Chua, April Gilbert, Giulia Rizzo, Carly S. Filgueira, Danilo Demarchi, Alessandro Grattoni

Chronic diseases such as hypertension and rheumatoid arthritis are persistent ailments that require personalized lifelong therapeutic management. However, the difficulty of adherence to strict dosing schedule compromises therapeutic efficacy and safety. Moreover, the conventional one-size-fits-all treatment approach is increasingly challenged due to the intricacies of inter- and intra-individual variabilities. While accelerated technological advances have led to sophisticated implantable drug delivery devices, flexibility in dosage and timing modulation to tailor precise treatment to individual needs remains an elusive goal. Here we describe the development of a subcutaneously implantable remote-controlled nanofluidic device capable of sustained drug release with adjustable dosing and timing. By leveraging a low intensity electric field to modify the concentration driven diffusion across a nanofluidic membrane, the rate of drug administration can be increased, decreased or stopped via Bluetooth remote command. We demonstrate in vitro the release modulation of enalapril and methotrexate, first-line therapeutics for treatment of hypertension and rheumatoid arthritis, respectively. Further, we show reliable remote communication and device biocompatibility via in vivo studies. Unlike a pulsatile release regimen typical of some conventional controlled delivery systems, our implant offers a continuous drug administration that avoids abrupt fluctuations, which could affect response and tolerability. Our system could set the foundation for an on-demand delivery platform technology for long term management of chronic diseases.

Original languageEnglish (US)
Pages (from-to)2192-2204
Number of pages13
JournalLab on a Chip
Volume19
Issue number13
DOIs
StatePublished - Jul 7 2019

PMID: 31169840

Altmetrics

Cite this

Standard

Remotely controlled nanofluidic implantable platform for tunable drug delivery. / Di Trani, Nicola; Silvestri, Antonia; Bruno, Giacomo; Geninatti, Thomas; Chua, Ying Xuan; Gilbert, April; Rizzo, Giulia; Filgueira, Carly S.; Demarchi, Danilo; Grattoni, Alessandro.

In: Lab on a Chip, Vol. 19, No. 13, 07.07.2019, p. 2192-2204.

Research output: Contribution to journalArticle

Harvard

Di Trani, N, Silvestri, A, Bruno, G, Geninatti, T, Chua, YX, Gilbert, A, Rizzo, G, Filgueira, CS, Demarchi, D & Grattoni, A 2019, 'Remotely controlled nanofluidic implantable platform for tunable drug delivery' Lab on a Chip, vol. 19, no. 13, pp. 2192-2204. https://doi.org/10.1039/c9lc00394k

APA

Di Trani, N., Silvestri, A., Bruno, G., Geninatti, T., Chua, Y. X., Gilbert, A., ... Grattoni, A. (2019). Remotely controlled nanofluidic implantable platform for tunable drug delivery. Lab on a Chip, 19(13), 2192-2204. https://doi.org/10.1039/c9lc00394k

Vancouver

Di Trani N, Silvestri A, Bruno G, Geninatti T, Chua YX, Gilbert A et al. Remotely controlled nanofluidic implantable platform for tunable drug delivery. Lab on a Chip. 2019 Jul 7;19(13):2192-2204. https://doi.org/10.1039/c9lc00394k

Author

Di Trani, Nicola ; Silvestri, Antonia ; Bruno, Giacomo ; Geninatti, Thomas ; Chua, Ying Xuan ; Gilbert, April ; Rizzo, Giulia ; Filgueira, Carly S. ; Demarchi, Danilo ; Grattoni, Alessandro. / Remotely controlled nanofluidic implantable platform for tunable drug delivery. In: Lab on a Chip. 2019 ; Vol. 19, No. 13. pp. 2192-2204.

BibTeX

@article{44f0dc230019445a9db3387ec47689b4,
title = "Remotely controlled nanofluidic implantable platform for tunable drug delivery",
abstract = "Chronic diseases such as hypertension and rheumatoid arthritis are persistent ailments that require personalized lifelong therapeutic management. However, the difficulty of adherence to strict dosing schedule compromises therapeutic efficacy and safety. Moreover, the conventional one-size-fits-all treatment approach is increasingly challenged due to the intricacies of inter- and intra-individual variabilities. While accelerated technological advances have led to sophisticated implantable drug delivery devices, flexibility in dosage and timing modulation to tailor precise treatment to individual needs remains an elusive goal. Here we describe the development of a subcutaneously implantable remote-controlled nanofluidic device capable of sustained drug release with adjustable dosing and timing. By leveraging a low intensity electric field to modify the concentration driven diffusion across a nanofluidic membrane, the rate of drug administration can be increased, decreased or stopped via Bluetooth remote command. We demonstrate in vitro the release modulation of enalapril and methotrexate, first-line therapeutics for treatment of hypertension and rheumatoid arthritis, respectively. Further, we show reliable remote communication and device biocompatibility via in vivo studies. Unlike a pulsatile release regimen typical of some conventional controlled delivery systems, our implant offers a continuous drug administration that avoids abrupt fluctuations, which could affect response and tolerability. Our system could set the foundation for an on-demand delivery platform technology for long term management of chronic diseases.",
author = "{Di Trani}, Nicola and Antonia Silvestri and Giacomo Bruno and Thomas Geninatti and Chua, {Ying Xuan} and April Gilbert and Giulia Rizzo and Filgueira, {Carly S.} and Danilo Demarchi and Alessandro Grattoni",
year = "2019",
month = "7",
day = "7",
doi = "10.1039/c9lc00394k",
language = "English (US)",
volume = "19",
pages = "2192--2204",
journal = "Lab on a Chip - Miniaturisation for Chemistry and Biology",
issn = "1473-0197",
publisher = "Royal Society of Chemistry",
number = "13",

}

RIS

TY - JOUR

T1 - Remotely controlled nanofluidic implantable platform for tunable drug delivery

AU - Di Trani, Nicola

AU - Silvestri, Antonia

AU - Bruno, Giacomo

AU - Geninatti, Thomas

AU - Chua, Ying Xuan

AU - Gilbert, April

AU - Rizzo, Giulia

AU - Filgueira, Carly S.

AU - Demarchi, Danilo

AU - Grattoni, Alessandro

PY - 2019/7/7

Y1 - 2019/7/7

N2 - Chronic diseases such as hypertension and rheumatoid arthritis are persistent ailments that require personalized lifelong therapeutic management. However, the difficulty of adherence to strict dosing schedule compromises therapeutic efficacy and safety. Moreover, the conventional one-size-fits-all treatment approach is increasingly challenged due to the intricacies of inter- and intra-individual variabilities. While accelerated technological advances have led to sophisticated implantable drug delivery devices, flexibility in dosage and timing modulation to tailor precise treatment to individual needs remains an elusive goal. Here we describe the development of a subcutaneously implantable remote-controlled nanofluidic device capable of sustained drug release with adjustable dosing and timing. By leveraging a low intensity electric field to modify the concentration driven diffusion across a nanofluidic membrane, the rate of drug administration can be increased, decreased or stopped via Bluetooth remote command. We demonstrate in vitro the release modulation of enalapril and methotrexate, first-line therapeutics for treatment of hypertension and rheumatoid arthritis, respectively. Further, we show reliable remote communication and device biocompatibility via in vivo studies. Unlike a pulsatile release regimen typical of some conventional controlled delivery systems, our implant offers a continuous drug administration that avoids abrupt fluctuations, which could affect response and tolerability. Our system could set the foundation for an on-demand delivery platform technology for long term management of chronic diseases.

AB - Chronic diseases such as hypertension and rheumatoid arthritis are persistent ailments that require personalized lifelong therapeutic management. However, the difficulty of adherence to strict dosing schedule compromises therapeutic efficacy and safety. Moreover, the conventional one-size-fits-all treatment approach is increasingly challenged due to the intricacies of inter- and intra-individual variabilities. While accelerated technological advances have led to sophisticated implantable drug delivery devices, flexibility in dosage and timing modulation to tailor precise treatment to individual needs remains an elusive goal. Here we describe the development of a subcutaneously implantable remote-controlled nanofluidic device capable of sustained drug release with adjustable dosing and timing. By leveraging a low intensity electric field to modify the concentration driven diffusion across a nanofluidic membrane, the rate of drug administration can be increased, decreased or stopped via Bluetooth remote command. We demonstrate in vitro the release modulation of enalapril and methotrexate, first-line therapeutics for treatment of hypertension and rheumatoid arthritis, respectively. Further, we show reliable remote communication and device biocompatibility via in vivo studies. Unlike a pulsatile release regimen typical of some conventional controlled delivery systems, our implant offers a continuous drug administration that avoids abrupt fluctuations, which could affect response and tolerability. Our system could set the foundation for an on-demand delivery platform technology for long term management of chronic diseases.

UR - http://www.scopus.com/inward/record.url?scp=85068145634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068145634&partnerID=8YFLogxK

U2 - 10.1039/c9lc00394k

DO - 10.1039/c9lc00394k

M3 - Article

VL - 19

SP - 2192

EP - 2204

JO - Lab on a Chip - Miniaturisation for Chemistry and Biology

T2 - Lab on a Chip - Miniaturisation for Chemistry and Biology

JF - Lab on a Chip - Miniaturisation for Chemistry and Biology

SN - 1473-0197

IS - 13

ER -

ID: 50622630